Working... Menu
Trial record 9 of 395 for:    PYY

The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00259246
Recruitment Status : Completed
First Posted : November 29, 2005
Last Update Posted : January 21, 2009
EC-FP6 (contract number: LHM-CT-2003-503041)
Aditech Pharma AB
Information provided by:
University of Copenhagen

Brief Summary:
The aim of the study is to compare fasting and postprandial PYY levels between overweight/obese and lean subjects during and after an infusion of saline, PYY1-36 or PYY3-36 and to evaluate the efects on appetite, energy intake and energy expenditure.

Condition or disease Intervention/treatment Phase
Obesity Drug: Peptide YY infusion Not Applicable

Detailed Description:
The study is a randomised dobbelblinded placebo controlled study with 24 male subjects ( 12 lean and 12 overweight/obese subjects). VAS scores are used to assess appetite and two ad libitum meals are served in the hours following the infusion. Energy expenditure is measured by ventilated hood system and blood is sampled during part of the study day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Fasting and Postprandial Response After Infusion of Saline, PYY1-36 and PYY3-36 and Effects on Appetite, Energy Intake and Energy Expenditure in Overweight/Obese Compared to Normalweight Subjects
Study Start Date : June 2004
Study Completion Date : November 2005

Primary Outcome Measures :
  1. Appetite
  2. Energy intake

Secondary Outcome Measures :
  1. Energy expenditure and substrate oxidation
  2. Blood parameters
  3. Blood pressure and heart rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2)
  • Body weight fluctuations < 5 kg over the past 2 months.
  • Blood pressure normal to mildly hypertensive (<159/99 mm Hg)
  • Non-elite athletes and not planning to change physical activity during the study.

Exclusion Criteria:

  • Any physiological or psychological illnesses that could influence the study results
  • Regular use of medicine
  • Smoking defined as <1 cigarette per day.
  • Substance abuse or dependence.
  • Blood donation within the past 3 months before entering the study
  • Drinking >21 alcoholic units/week.
  • Food allergies.
  • Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00259246

Sponsors and Collaborators
University of Copenhagen
EC-FP6 (contract number: LHM-CT-2003-503041)
Aditech Pharma AB
Layout table for investigator information
Principal Investigator: Arne Astrup, Professor Department of Human Nutrition, RVAU

Layout table for additonal information Identifier: NCT00259246     History of Changes
Other Study ID Numbers: B208,1
First Posted: November 29, 2005    Key Record Dates
Last Update Posted: January 21, 2009
Last Verified: April 2005